NEW YORK, Aug. 11, 2016 /PRNewswire/ --
The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment. The relative complexity, costs and patient logistics associated with IV infusion relative to other routes of administration is creating interest in post-launch re-engineering of IV drugs to allow them to be administered subcutaneously. A number of technology approaches are currently being employed to accomplish this migration. By pursuing intravenous-to-subcutaneous drug markets, drug owners are finding they can achieve a number of competitive advantages.
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations
will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective.
Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.
What You Will Learn
- What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?
-What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?
- What are the major factors driving intravenous-to-subcutaneous drug re-engineering?
- How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?
- What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?
- Who are the significant players in this segment? What are their strategies? Who are their alliance partners?
Read the full report: http://www.reportlinker.com/p04053510-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001